Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$0.3.

  • Tarsus Pharmaceuticals' EPS (Basic) rose 5081.97% to -$0.3 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.01, marking a year-over-year increase of 4668.44%. This contributed to the annual value of -$3.07 for FY2024, which is 3348.76% up from last year.
  • Tarsus Pharmaceuticals' EPS (Basic) amounted to -$0.3 in Q3 2025, which was up 5081.97% from -$0.48 recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' EPS (Basic) ranged from a high of $0.31 in Q2 2021 and a low of -$1.28 during Q3 2023
  • Its 5-year average for EPS (Basic) is -$0.7, with a median of -$0.7 in 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' EPS (Basic) soared by 12520.33% in 2021 and then plummeted by 38750.0% in 2023.
  • Tarsus Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.7 in 2021, then surged by 30.49% to -$0.49 in 2022, then crashed by 159.18% to -$1.27 in 2023, then soared by 51.66% to -$0.61 in 2024, then soared by 51.13% to -$0.3 in 2025.
  • Its EPS (Basic) stands at -$0.3 for Q3 2025, versus -$0.48 for Q2 2025 and -$0.64 for Q1 2025.